Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.
Org chart
Collapse
Board & advisors
Teams
Offices
Tempus Labs
33 followers
Adaptive Biotechnologies
20 followers
Genesis Therapeutics
5 followers
Sling Therapeutics
2 followers
Monte Rosa Therapeutics
3 followers
Asimov
3 followers
Thermo Fisher Scientific
286 followers
Genentech
227 followers
Gilead Sciences
215 followers
Regeneron
184 followers
Biogen
167 followers
Vertex Pharmaceuticals
111 followers